7 Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van 2 Furthermore, activation of the B-cell antigen receptor pathway resulted in a dramatic increase in the expression of BTK in murine B cells in vitro and in intact animal model systems.
We postulated that B-cell antigen receptor pathway-induced BTK protein observed in normal murine B-lymphocytes 3 and ibrutinib-mediated decline in BTK levels in CLL B-cells in TCL1 mice 8 should also occur during ibrutinib therapy of human CLL. To test this hypothesis, we obtained circulating CLL cells from patients on ibrutinib. The present study was carried out in lymphocytes isolated from peripheral blood samples of patients with CLL who received 420 mg/day of ibrutinib on phase II and III clinical trials. All participants signed written informed consent forms in accordance with the Declaration of Helsinki, and the laboratory protocols were approved by the Institutional Review Board at the University of Texas MD Anderson Cancer Center. CLL cells were isolated from peripheral blood samples, protein was extracted, and analyzed for quantitation using immunoblots.
Similar to Chen et al., 8 we observed a decline in BTK protein in the circulating leukemia cells in the peripheral blood of patients after 4 weeks of ibrutinib therapy (Figure 1 ). This was associated with a decrease in phospho-and total-CXCR4. In contrast to the prior report in murine CLL cells, 8 where cell surface (membrane) as well as and intracellular expression were evaluated, in the current work, we analyzed only total intracellular CXCR4 protein levels. This decrease in CXCR4 receptor level may be owing to diminished Figure 1 . Impact of ibrutinib therapy on BTK-and CXCR4-associated proteins in primary CLL cells. Primary CLL cells from three patients (Pt) were isolated fresh from peripheral blood samples before treatment (baseline, designated as 0 week), and 4 weeks after 420 mg daily oral doses of ibrutinib. Blood samples were collected in green-top tubes and CLL cells were isolated by Ficoll-Hypaque gradient. Cell pellets were prepared for two immunoblots. The first immunoblot was used for total BTK (BD Biosciences 611116), and phospho-(Abcam 74012) and total CXCR4 (Abcam 58176). GAPDH (Novus NB600-502) was blotted for loading control. The second immunoblot (below dashed line) was used to test phospho-(Cell Signaling 2054) and total PKC (Abnova H00005587-B01P), and total GRK6 (Cell Signaling 5878) and Pim-1 (Sigma SAB1404205). GAPDH (Novus NB600-502) served as a protein loading control.
phosphorylation of the receptor, which may be due to three different upstream kinases (Pim1, GRK6 and PKCμ). Total protein levels of all three kinases appear to decrease after 4 weeks of ibrutinib therapy. In the murine Tcl-1 model system, reduction in phospho-PKC and total Pim-1 kinase was reported. 8 Because a decrease in BTK protein during ibrutinib therapy has clinical and pharmacological consequences, we further investigated changes in the total protein levels in additional patients. It is noteworthy that as a corollary to almost complete occupation of BTK protein by ibrutinib at this dose (420 mg per day), a decline in phospho-BTK 9 was observed in circulating CLL lymphocytes after 2, 4 and 12 weeks of continuous therapy. Quantitation of total BTK protein in 2, 5 and 2 patient samples at 2, 4 and 12 weeks, respectively of ibrutinib showed a statistically significant timedependent decline in the level of total BTK protein compared with the untreated (baseline) sample (Figure 2a) . Because the number of samples is low at each time point, comparison of all samples was done to determine overall statistical significance (P = 0.0001). This reduction in protein level was also observed at the mRNA transcript level (Figure 2b ), albeit to a lesser extent. Compared with the baseline value (0 week), the mean values were 0.7, 0.5 and 0.35 at 2, 4 and 12 weeks, respectively (P = 0.0003 for the whole group).
As mentioned above, the mechanism of action of ibrutinib in CLL relies on almost complete and irreversible covalent binding of drug to the target, that is, BTK. Hence, drug (ibrutinib) to substrate (BTK) stoichiometry is important in identifying quantitative relationships and optimal dosing of ibrutinib. On the basis of our current data in human CLL cells during ibrutinib therapy, one could postulate that after a few weeks of ibrutinib, the target protein will decrease, suggesting that a lower dose will suffice to stochiometrically inhibit this kinase. We have designed a pilot protocol to test this hypothesis wherein each patient will receive progressively lower ibrutinib doses over three cycles of therapy.
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